286 related articles for article (PubMed ID: 26266428)
1. Inhibition of Pathologic Corneal Neovascularization by Topical Application of a Novel Peptide In Vivo.
Lu Y; Xu Y; Gu Q; Xu X
Cornea; 2015 Oct; 34(10):1295-302. PubMed ID: 26266428
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of a novel PIGF-1 derived peptide, ZY-1, on corneal neovascularization in vitro and in vivo.
Lu Y; Zheng Y; Ai J; Xu X
Discov Med; 2016 May; 21(117):349-61. PubMed ID: 27355331
[TBL] [Abstract][Full Text] [Related]
3. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
4. A Novel Small Peptide H-KI20 Inhibits Retinal Neovascularization Through the JNK/ATF2 Signaling Pathway.
Wang R; Xu Y; Niu C; Gao X; Xu X
Invest Ophthalmol Vis Sci; 2021 Jan; 62(1):16. PubMed ID: 33439229
[TBL] [Abstract][Full Text] [Related]
5. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of topical VEGF neutralization at the cornea.
Bock F; Onderka J; Rummelt C; Dietrich T; Bachmann B; Kruse FE; Schlötzer-Schrehardt U; Cursiefen C
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2095-102. PubMed ID: 19151400
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of corneal angiogenesis by local application of vasostatin.
Wu PC; Yang LC; Kuo HK; Huang CC; Tsai CL; Lin PR; Wu PC; Shin SJ; Tai MH
Mol Vis; 2005 Jan; 11():28-35. PubMed ID: 15660022
[TBL] [Abstract][Full Text] [Related]
8. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Zhang Z; Ma JX; Gao G; Li C; Luo L; Zhang M; Yang W; Jiang A; Kuang W; Xu L; Chen J; Liu Z
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effect of Topical Aflibercept on Corneal Neovascularization in Rabbits.
Park YR; Chung SK
Cornea; 2015 Oct; 34(10):1303-7. PubMed ID: 26114826
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
Gal-Or O; Livny E; Sella R; Nisgav Y; Weinberger D; Livnat T; Bahar I
Cornea; 2016 Jul; 35(7):991-6. PubMed ID: 27124775
[TBL] [Abstract][Full Text] [Related]
12. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1.
Zheng Y; Gu Q; Xu X
Acta Ophthalmol; 2012 Nov; 90(7):e512-23. PubMed ID: 22994140
[TBL] [Abstract][Full Text] [Related]
14. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.
Türkcü FM; Cinar Y; Türkcü G; Sahin A; Cingü AK; Yüksel H; Sahin M; Yıldırım A; Caça I
Cutan Ocul Toxicol; 2014 Jun; 33(2):138-44. PubMed ID: 23859535
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
16. Effect of topical epigallocatechin gallate on corneal neovascularization in rabbits.
Koh CH; Lee HS; Chung SK
Cornea; 2014 May; 33(5):527-32. PubMed ID: 24608256
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
Dastjerdi MH; Saban DR; Okanobo A; Nallasamy N; Sadrai Z; Chauhan SK; Hajrasouliha AR; Dana R
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2411-7. PubMed ID: 19892863
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
